Author:
Li Yu-Ling,Tang Jia-Ming,Chen Xiao-Yun,Luo Bing,Liang Guo-Hua,Qu Qian,Lu Zi-Yuan
Funder
Science and Technology Planning Project of Guangdong Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology
Reference30 articles.
1. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and %3e 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511–8.
2. Druker BJ, O'Brien SG, Jorge C, Jerald R. Chronic myelogenous leukemia. Curr Opin Oncol. 2001;13:3.
3. Ruibao R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–83.
4. Moraes GND, Souza PS, Costas FCDF, Vasconcelos FC, Maia RC. The Interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. Leukemia Res Treatment. 2012;2012:671702.
5. Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234:12369–84.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献